

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/273261720>

# Structure–activity relationships of substituted 1H-indole–2-carboxamides as CB1 receptor allosteric modulators

ARTICLE *in* BIOORGANIC & MEDICINAL CHEMISTRY · MARCH 2015

Impact Factor: 2.79 · DOI: 10.1016/j.bmc.2015.02.058

---

READS

20

## 8 AUTHORS, INCLUDING:



**Jun-Xu Li**

University at Buffalo, The State University of New York

74 PUBLICATIONS 633 CITATIONS

SEE PROFILE



**Brian Frazier Thomas**

RTI International

81 PUBLICATIONS 2,726 CITATIONS

SEE PROFILE



**Terry P Kenakin**

University of North Carolina at Chapel Hill

189 PUBLICATIONS 9,792 CITATIONS

SEE PROFILE



**Yanan Zhang**

Research Triangle Institute

61 PUBLICATIONS 730 CITATIONS

SEE PROFILE



Contents lists available at ScienceDirect

## Bioorganic &amp; Medicinal Chemistry

journal homepage: [www.elsevier.com/locate/bmc](http://www.elsevier.com/locate/bmc)

# Structure–activity relationships of substituted 1*H*-indole-2-carboxamides as CB1 receptor allosteric modulators

Thuy Nguyen<sup>a,†</sup>, Nadezhda German<sup>a,†,‡</sup>, Ann M. Decker<sup>a</sup>, Jun-Xu Li<sup>b</sup>, Jenny L. Wiley<sup>a</sup>, Brian F. Thomas<sup>a</sup>, Terry P. Kenakin<sup>c</sup>, Yanan Zhang<sup>a,\*</sup>

<sup>a</sup> Research Triangle Institute, Research Triangle Park, NC 27709, United States

<sup>b</sup> Department of Pharmacology and Toxicology, University at Buffalo, The State University of New York, Buffalo, NY 14214, United States

<sup>c</sup> Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States

## ARTICLE INFO

### Article history:

Received 13 January 2015

Revised 20 February 2015

Accepted 26 February 2015

Available online 7 March 2015

### Keywords:

CB1 receptor

Allosteric modulators

Org compounds

Structure–activity relationship

## ABSTRACT

A series of substituted 1*H*-indole-2-carboxamides structurally related to compounds Org27569 (**1**), Org29647 (**2**) and Org27759 (**3**) were synthesized and evaluated for CB1 allosteric modulating activity in calcium mobilization assays. Structure–activity relationship studies showed that the modulation potency of this series at the CB1 receptor was enhanced by the presence of a diethylamino group at the 4-position of the phenyl ring, a chloro or fluoro group at the C5 position and short alkyl groups at the C3 position on the indole ring. The most potent compound (**45**) had an IC<sub>50</sub> value of 79 nM which is ~2.5 and 10 fold more potent than the parent compounds **3** and **1**, respectively. These compounds appeared to be negative allosteric modulators at the CB1 receptor and dose-dependently reduced the E<sub>max</sub> of agonist CP55,940. These analogs may provide the basis for further optimization and use of CB1 allosteric modulators.

© 2015 Elsevier Ltd. All rights reserved.

## 1. Introduction

The cannabinoid type 1 (CB1) receptor is a key component of the endocannabinoid system, which also includes the CB2 receptor, endocannabinoids and enzymes involved in the biosynthesis and degradation of these endogenous ligands.<sup>1,2</sup> Since the cloning of CB1 and CB2 receptors in the 1990s, considerable research efforts have been directed at understanding their physiological and pathological roles. The endocannabinoid system has been shown to be involved in a number of physiological processes, including cardiovascular regulation, appetite control, learning and memory, and pain processing.<sup>3–5</sup> The CB1 receptor is one of the most abundant G-protein coupled receptor (GPCR) expressed in the central nervous system (CNS), and is predominantly expressed at pre-synaptic nerve terminals, where it plays a key role in inhibition of transmitter release. The CB1 receptor is also found in several peripheral tissues, but at much lower concentrations. The CB2 receptor is mainly expressed in immune cells, and is involved in modulation of

cytokine release and immune cell migration. The modulation of the CB1 receptor has been targeted in the treatment of a number of disorders such as obesity, drug addiction, pain, inflammation, gastrointestinal diseases, multiple sclerosis, psychosis, schizophrenia, and osteoporosis.<sup>4,6</sup>

A large number of selective and non-selective agonists and antagonists have been developed for the CB1 receptor to date.<sup>7–9</sup> More recently, there is convincing evidence suggesting that the CB1 receptor also contains allosteric binding site(s) that can be modulated by endogenous and/or synthetic small molecules, and the structural requirements of allosteric ligands are distinctly different from orthosteric ligands.<sup>10–12</sup> A number of novel compounds have been reported to be CB1 allosteric modulators, including Org27569, Org29647, Org27759 (**1–3**),<sup>13</sup> PSNCBAM-1 (**4**),<sup>14</sup> RTI-371 (**5**),<sup>15</sup> and lipoxin A4 (**6**) (Fig. 1).<sup>16</sup> Compared to orthosteric ligands, allosteric ligands generally do not disrupt physiological signaling processes and may provide improved selectivity as allosteric sites are less structurally conserved than the corresponding orthosteric site among receptor subtypes. In addition, allosteric modulators may offer a significant clinical advantage in drug safety profiles because of the ‘ceiling’ effect, the phenomenon in which a drug reaches a maximum effect so that increasing the drug dosage does not increase its effectiveness, which results from their dependence on endogenous ligands for signaling.<sup>17–19</sup> The small

\* Corresponding author. Tel.: +1 919 541 1235; fax: +1 919 541 6499.

E-mail address: [yzhang@rti.org](mailto:yzhang@rti.org) (Y. Zhang).

<sup>†</sup> These authors contributed equally to this work.

<sup>‡</sup> Current address: Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, United States.

molecule CB1 allosteric modulators developed to date have been demonstrated to be allosteric enhancers of agonist binding and affinity and allosteric inhibitors of agonist signaling efficacy in several *in vitro* functional assays.<sup>20,21</sup> Interestingly, **1** did not enhance or block CB1 agonist-induced effects in several animal models in mice (antinociception, catalepsy, and hypothermia) and appeared to exhibit its anorectic effect through non-CB1 specific mechanisms.<sup>22</sup> While we have seen similar negative results in catalepsy and antinociception in rats, Org27569 attenuated the hypothermic effects of CB1 receptor agonists CP55940 and anandamide.<sup>23</sup> Moreover, we also found that **1** resulted in a dose-related attenuation of both cue- and drug-induced reinstatement of cocaine- and methamphetamine-seeking behavior.<sup>24</sup> Finally, **1** showed high pharmacological selectivity against over forty GPCRs including those commonly involved in drug addictions.<sup>24</sup> Together, these results suggest that the observed effects of **1** were likely mediated through negative modulation of CB1 receptors.

Since the discovery of **1–3**, several structure–activity relationship (SAR) studies on the 1*H*-indole-2-carboxamide scaffold have been reported. Most of these studies have focused on modifications on the indole and phenyl rings A and B (Fig. 1). Piscitelli et al. examined a number of 4-substitutions on the phenyl ring B and discovered that piperidinyl or dimethylamino groups at the 4-position of the phenyl ring were preferred for CB1 activity and the carboxamide functionality was required (Fig. 1).<sup>25</sup> Subsequent work found that longer alkyl side chains with up to 9 carbon units at the C3 position of indole ring A could retain activity, whereas linkers other than an ethylene between the amide bond and the phenyl ring B resulted in total loss of activity.<sup>26–28</sup> In an attempt to expand our understanding of the structure–activity relationship on this scaffold, we have designed additional analogs by (i) exploring different substituents at the 4-, 3-, 2-positions of the phenyl ring B, (ii) examining several rigid cyclic ring linkers between the phenyl and the indole rings, and (iii) investigating the effects of shorter alkyl side chain at the C3 position and halogenations at the C5 position of the indole ring A. Here, we report the synthesis of these 1*H*-indole-2-carboxamide analogs and the evaluation of CB1 and CB2 activities in fluorometric imaging plate reader (FLIPR) based calcium mobilization assays.

## 2. Methods

### 2.1. Chemistry

The target compounds **12**, **16–37**, **42–49** were synthesized following procedures depicted in Schemes 1 and 2. Scheme 1 describes the synthesis of the key intermediate 5-chloro-3-ethyl-1*H*-indole-2-carboxylic acid (**11**) and target compounds **16–37**. The commercially available 5-chloro-1*H*-indole-2-carboxylic acid (**7**) was protected as ethyl ester **8** which underwent Friedel Crafts acylation to yield **9**.<sup>29</sup> Reduction of **9** by triethylsilane in trifluoroacetic acid at room temperature gave **10** which was hydrolyzed in aqueous sodium hydroxide and ethanol to furnish the intermediate **11**.<sup>26,27</sup> Amide coupling between **11** and 4- or 3-nitrophenylethylamine in the presence of BOP provided **12** and **13** which were reduced by Raney nickel-catalyzed transfer hydrogenation using hydrazine in ethanol at 50 °C to give **14** and **15**. Reductive amination of amines **14** and **15** with the corresponding aldehydes provided the target compounds **16–20**. Compounds **21–23** were obtained by amide coupling of amine **14** and corresponding acids or acid chloride. Similarly, compounds **24–37** were prepared by standard amide coupling between acid **11** and the appropriate amines.

The *N,N*-diethylphenylethylamine (**40**) and 4-piperidinylphenylethylamine (**41**) used to synthesize compounds **1** and **42–49** were

prepared according to Scheme 2. 4-Nitrophenylethylamine (**38**) underwent Boc-protection and Raney nickel-catalyzed reduction with hydrazine hydrate in ethanol at 50 °C to give **39**, which was then converted to **40** by reductive amination with acetaldehyde in the presence of sodium triacetoxyborohydride in 1,2-dichloroethane. Cyclization of **39** with 1,5-dibromopentane in aqueous potassium carbonate solution under microwave irradiation furnished **41**.<sup>30</sup> After removal of the Boc protective group, **40** and **41** were coupled with the corresponding 1*H*-indole-2-carboxylic acids to afford the target compounds **1**, and **42–49**.


### 2.2. Biological assays

The activity of the target compounds at CB1 and CB2 receptors was evaluated in FLIPR-based calcium mobilization functional assays. The calcium mobilization assays have been used routinely in our laboratory to characterize cannabinoid compounds and demonstrate correlation with other cannabinoid assays such as binding and GTP- $\gamma$ -S.<sup>31–33</sup> Briefly, CHO-RD-HGA16 cells stably expressing either human CB1 or CB2 receptors were loaded with Calcium 5 dye (Molecular Devices, USA), and treated with test compounds in the presence of the EC<sub>80</sub> concentration of the agonist CP55,940 (100 nM). For the CB1 receptor, IC<sub>50</sub> values were obtained from the plots of kinetic reduction fluorescence signals against the log of compound concentrations. For the CB2 receptor, all compounds were initially screened at 10  $\mu$ M as antagonists and IC<sub>50</sub> was obtained only if >50% inhibition was observed. Finally, all compounds were also tested for agonist activity at 10  $\mu$ M at both receptors.


## 3. Results and discussion

Using **1** as the lead compound (IC<sub>50</sub> = 853 nM), we first investigated the effect of substitution on the phenyl ring B (Table 1). Previous studies have focused on 4-substitutions on this phenyl ring, particularly 4-amino groups such as piperidinyl and dimethylamino.<sup>25–27</sup> Here we introduced a number of other amino groups at several positions. The activity of the piperidine ring-opened series (compounds **16–19**) was found to be sensitive to the length of the alkyl substituent. The activity of the dialkylamino analogs increased from methyl (**16**) to ethyl (**17**) and then declined as the side chain was extended further to a propyl group (**18**). The hexyl analog **19** was only moderately active. Together, these implicate a limited space at this region of the CB1 binding pocket. The most potent analog was **17** with the diethylamino group at the 4-position (IC<sub>50</sub> 483 nM), 2-fold more potent than **1**). All three acylated analogs (**21–23**) were devoid of any activity up to 10  $\mu$ M. The activity also decreased with the non-substituted analog (**24**) or when the nitrogen was replaced by other substituents with different electronic properties (**12**, **24–27**), in agreement with earlier findings.<sup>11</sup> Together, these results suggest that a basic electron-accepting nitrogen was preferred at the 4-position for CB1 modulating activity.

While the 4-position on the phenyl ring has been previously investigated, substitutions at the other positions have not been reported. Interestingly, we found that the 4- and 3-position on the phenyl ring preferred different substituents. The 4-position appeared to favor the dialkylamino substituted series. Switching the dimethylamino group from the 4- to 3-position resulted in abolishment of CB1 inhibitory activity. **16** had an IC<sub>50</sub> of 787 nM, whereas the 3-position substituted analog **20** displayed no potency up to 10  $\mu$ M. However, the chloro group preferred a 3-position substitution pattern as **29** had an IC<sub>50</sub> of 831 nM while **25** and **28** had IC<sub>50</sub> values of 2500 nM and 5810 nM, respectively. Methoxy was less affected by substituent position with **26** and **30**, both



**Figure 1.** Structures of several reported CB1 allosteric modulators.




**Scheme 1.** Synthesis of the key intermediate **11** and target compounds **12** and **16–37**. Reagents and conditions: (a) EtOH, 5% HCl, reflux, 18 h; (b) acetic anhydride, AlCl<sub>3</sub>, 1,2-dichloroethane, reflux, overnight; (c) Et<sub>3</sub>SiH, CF<sub>3</sub>COOH, rt, 3 h; (d) NaOH, EtOH, reflux, 3 h; (e) corresponding amine, BOP, DIEA, DMF, rt, overnight; (f) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, Raney-Ni, ethanol, 50 °C, 1 h; (g) formaldehyde, NaCNBH<sub>3</sub>, MeOH, AcOH, rt, 24 h; (h) corresponding aldehyde, Na(OAc)<sub>3</sub>BH, 1,2-dichloroethane, rt, 24 h; (i) acid chloride, Et<sub>3</sub>N, THF, reflux, 16 h.

displaying moderate potency. This substitution difference between the 3- and 4-positions seem to suggest less steric tolerance at the 3-positions where only a chloro, but not the dimethylamino or methoxy groups are tolerated. A combination of 3- and 4-substituents did not provide any enhancement to the potency (**33** and **34**), and even reduced the potency as in the case of **32** (3'-OH, 4'-OCH<sub>3</sub>), consistent with earlier observations on limited spatial pocket at these positions.

Compound **2** with a pyrrolidinyl linker between the amide bond and the phenyl ring showed significantly reduced potency compared to **1** and **3** (Table 2). Several other linkers were briefly examined and none of the phenyl (**35**) or piperazine (**36** and **37**) analogs

showed CB1 inhibitory effects at concentrations up to 10  $\mu$ M. Hence, it appears that a flexible alkyl linker is important to CB1 activity, which is in agreement with Khurana et al. who showed that the ethylene moiety was the optimal linker.<sup>27</sup>

Next we turned our attention to the indole ring A where we investigated the effect of fluoro and chloro groups at the C5 position and the length of the alkyl side chain at the C3 position on the indole ring. These analogs have either a piperidinyl group as in **1** or a diethylamino group as in **17**, the most potent compounds from Table 1, at the 4-position of the phenyl ring B. In general, the diethylamino analogs (**17**, **42–45** having IC<sub>50</sub> values ranging from 79 to 484 nM) were more potent than the piperidinyl analogs (**1**,



**Scheme 2.** Synthesis of compounds **1**, and **42–49**. Reagents and conditions: (a)  $\text{Boc}_2\text{O}$ , aq NaOH, 1,4-dioxane, rt, 16 h; (b)  $\text{N}_2\text{H}_4 \cdot \text{H}_2\text{O}$ , Raney-Ni, ethanol, 50 °C, 1 h; (c) acetaldehyde,  $\text{Na}(\text{OAc})_3\text{BH}$ , 1,2-dichloroethane, rt, 16 h; (d) 1,5-dibromopentane,  $\text{K}_2\text{CO}_3$ ,  $\text{H}_2\text{O}$ , microwave irradiation, 120 °C, 20 min (e) TFA, DCM, rt, 16 h; (f) corresponding 1*H*-indole-2-carboxylic acids, BOP, DIEA, DMF, rt, 16 h.

**Table 1**

Compounds **1**, **12**, **16–34** and their inhibitory activity at the CB1 receptor

#	R	Ring B	
		Cl	R
#	R	CB1 $\text{IC}_{50}^a$ (nM)	CB2 % inhibition of CP55,940 <sup>b</sup>
<b>1</b>	4'-N <sub>2</sub> Et <sub>2</sub>	853 ± 130	−16.4 ± 1.8
<b>12</b>	4'-NO <sub>2</sub>	5740 ± 930	34.8 ± 22.6
<b>16</b>	4'-NMe <sub>2</sub>	787 ± 110	−12.7 ± 2.8
<b>17</b>	4'-NEt <sub>2</sub>	483 ± 60	−44 ± 11
<b>18</b>	4'-NHPr <sub>2</sub>	1800 ± 480	−37.4 ± 6.8
<b>19</b>	4'-NH(CH <sub>2</sub> ) <sub>5</sub> CH <sub>3</sub>	3620 ± 790	−35.0 ± 4.6
<b>20</b>	3'-NMe <sub>2</sub>	>10,000	−3.7 ± 4.3
<b>21</b>	4'-NHCOCH <sub>3</sub>	>10,000	−3.3 ± 11.7
<b>22</b>	4'-NHCO(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	>10,000	43.0 ± 3.2
<b>23</b>	4'-NHCO(CH <sub>2</sub> ) <sub>4</sub> CH <sub>3</sub>	>10,000	1.0 ± 0.6
<b>24</b>	H	3150 ± 260	−6.2 ± 25.3
<b>25</b>	4'-Cl	2500 ± 410	−4.8 ± 30.0
<b>26</b>	4'-OCH <sub>3</sub>	2560 ± 110	−11.2 ± 19.6
<b>27</b>	4'-tBu	2430 ± 430	−18.0 ± 35.4
<b>28</b>	2'-Cl	5810 ± 990	28.5 ± 24.0
<b>29</b>	3'-Cl	831 ± 190	24.8 ± 28.6
<b>30</b>	3'-OCH <sub>3</sub>	2100 ± 170	−6.0 ± 19.0
<b>31</b>	3'-OH	>10,000	−0.1 ± 21.4
<b>32</b>	3'-OH,4'-OCH <sub>3</sub>	>10,000	−7.0 ± 19.6
<b>33</b>	3',4'-DiCl	2170 ± 530	−3.2 ± 10.8
<b>34</b>	3'-O 4'-O	4320 ± 190	25.8 ± 22.1

<sup>a</sup> Against  $\text{EC}_{80}$  (100 nM) of CP55,940. Values are the mean ± SEM of at least three independent experiments in duplicate.

<sup>b</sup> Percent inhibition of CP55,940  $\text{EC}_{80}$  (100 nM). Values are the mean ± SEM of at least two independent experiments in duplicate.

**46–49** having  $\text{IC}_{50}$  values from 212 to 853 nM). Compound **45** was the most potent compound in this series with an  $\text{IC}_{50}$  value of 79 nM, 6-fold more potent than compound **17**, and 2.5-fold more potent than compound **3**. The CB1 inhibitory effect seems to be sensitive to the substituent on the C3 position on the indole ring. A smaller group like H or Me is preferred to an ethyl group. On the other hand, F and Cl at the C5 position was not the determining factor in CB1 activity. While **45** and **49** with a 5-chloro were more

**Table 2**

Compounds **2**, **35–37** and their inhibitory activity at the CB1 receptor

#	R	CB1 $\text{IC}_{50}^a$ (nM)	CB2 % inhibition of CP55,940 <sup>b</sup>
<b>2</b>		4760 ± 710	−6.2 ± 2.5
<b>35</b>		>10,000	−19.2 ± 11.5
<b>36</b>		>10,000	−28.0 ± 25.9
<b>37</b>		>10,000	−31.1 ± 18.8

<sup>a</sup> Against  $\text{EC}_{80}$  (100 nM) of CP55,940. Values are the mean ± SEM of at least three independent experiments in duplicate.

<sup>b</sup> Percent inhibition of CP55,940  $\text{EC}_{80}$  (100 nM). Values are the mean ± SEM of at least two independent experiments in duplicate.

potent than **44** and **48** with a 5-fluoro substituent, **17** and **1** were less active than their counterparts **42** and **46**.

When tested at the CB2 receptor, none of the compounds showed >35% of inhibition of the  $\text{EC}_{80}$  of CP55,940 at concentrations of up to 10 μM and therefore, their  $\text{IC}_{50}$  value was not determined (Tables 1–3). All compounds were also screened at 10 μM for agonist activity at both the CB1 and CB2 receptors. None of the compounds displayed significant agonist activity at either receptor (less than 30% of CP55,940  $E_{\text{max}}$ ) (Supporting information). As depicted in Figure 2, compounds **1**, **3** and **45** all dose-dependently decreased the  $E_{\text{max}}$  of agonist CP55,940 in the same manner. Thus, this suggests that these compounds exerted their effects by an allosteric mechanism.<sup>20,21</sup>

#### 4. Conclusions

The identification of the CB1 allosteric binding site and its interesting pharmacological response have prompted investigation of its function and development of molecular probes to help elucidate

**Table 3**Compounds **1**, **3**, **17**, **42–49** and their inhibitory activity at the CB1 receptor

#	X	R <sub>1</sub>	R <sub>2</sub>	Ring B	
				Ring A	Ring B
#	X	R <sub>1</sub>	R <sub>2</sub>	CB1 IC <sub>50</sub> <sup>a</sup> (nM)	CB2 % inhibition of CP55,940 <sup>b</sup>
<b>1</b>	Cl	Et		853 ± 130	−16.4 ± 1.8
<b>3</b>	F	Et	NMe <sub>2</sub>	205 ± 34	−20.4 ± 2.4
<b>17</b>	Cl	Et	NEt <sub>2</sub>	483 ± 60	−44.4 ± 11.1
<b>42</b>	F	Et	NEt <sub>2</sub>	361 ± 49	−25.7 ± 10.7
<b>43</b>	F	Me	NEt <sub>2</sub>	151 ± 20	−21.8 ± 6.5
<b>44</b>	F	H	NEt <sub>2</sub>	318 ± 53	−23.8 ± 5.2
<b>45</b>	Cl	H	NEt <sub>2</sub>	79 ± 7	0.7 ± 9.8
<b>46</b>	F	Et		605 ± 93	−33.1 ± 16.3
<b>47</b>	F	Me		279 ± 51	−8.2 ± 5.8
<b>48</b>	F	H		319 ± 76	20.8 ± 5.9
<b>49</b>	Cl	H		212 ± 41	15.0 ± 9.8

<sup>a</sup> Against EC<sub>80</sub> (100 nM) of CP55,940. Values are the mean ± SEM of at least three independent experiments in duplicate.


<sup>b</sup> Percent inhibition of CP55,940 EC<sub>80</sub> (100 nM). Values are the mean ± SEM of at least two independent experiments in duplicate.

the pharmacology of the CB1 receptor. To this end, we have designed and synthesized a series of 1*H*-indole-2-carboxamide derivatives by varying substituents on the phenyl ring B, linker between the amide bond and phenyl ring B, as well as modifying the halogen substituent at the 5-position and alkyl side chain at the 3-position on the indole ring A. In general, an electron-donating group at the 4-position on the phenyl ring, as well as an ethylene linker, were important features of CB1 modulating activity. On the indole ring A, a small side chain (H or Me) was preferred while the difference in effects of the fluoro and chloro on CB1 activity was not significant. These compounds showed excellent selectivity against the CB2 receptor and did not have any significant agonist activity at either receptor in the calcium mobilization assays. Several compounds showed similar or improved potency compared to the parent compounds. Compound **45** had an IC<sub>50</sub> of 79 nM, ~2.5 and 10 fold more potent than **3** and **1**, respectively. In conclusion, CB1 allosteric modulators of this structural scaffold hold promising potential for further development as effective probes of the allosteric site(s) of the CB1 receptor.

## 5. Experimental

### 5.1. Chemistry

All solvents and chemicals were reagent grade. Unless otherwise mentioned, all reagents and solvents were purchased from commercial vendors and used as received. Flash column chromatography was carried out on a Teledyne ISCO CombiFlash Rf system using prepacked columns. Solvents used include hexane, ethyl acetate (EtOAc), dichloromethane, and, methanol. Microwave reactions were carried out on a CEM Discover microwave synthesizer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance DPX-300 (300 MHz) spectrometer and were determined in chloroform-*d*, methanol-*d*<sub>4</sub>, or DMSO-*d*<sub>6</sub> with tetramethylsilane (TMS)



**Figure 2.** Allosteric modulation of compounds **1**, **3**, and **45** in the CB1 calcium mobilization assay.

(0.00 ppm) or solvent peaks as the internal reference. Chemical shifts are reported in ppm relative to the reference signal and coupling constant (*J*) values are reported in hertz (Hz). Thin layer chromatography (TLC) was performed on EMD precoated silica gel 60 F254 plates and spots were visualized with UV light or iodine staining. Low resolution mass spectra were obtained using a Waters Alliance HT/Micromass ZQ system (ESI). All test compounds were greater than 95% pure as determined by HPLC on an Agilent 1100 system using an Agilent Zorbax SB-Phenyl, 2.1 mm × 150 mm, 5 μm column with gradient elution using the mobile phases (A) H<sub>2</sub>O containing 0.1% CF<sub>3</sub>COOH and (B) MeCN, with a flow rate of 1.0 mL/min.

#### 5.1.1. Ethyl 5-chloro-1*H*-indole-2-carboxylate (**8**)

To a flask containing 5% HCl solution (50 ml) and ethanol (50 ml) was added 5-chloro-1*H*-indole-2-carboxylic acid (2 g, 10.22 mmol). The reaction was refluxed for 18 h. After that, the reaction volume was reduced to half in vacuo. The product precipitated out and was filtered off. The mother liquor was evaporated to dryness and the solid residue was washed with a mixture of acetone and water to an additional crop of the product as off-white solid (2.18 g, 95% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.42 (t, *J* = 7.2, 3H), 4.42 (q, *J* = 7.2, 2H), 7.15 (m, 1H), 7.27 (m, 1H), 7.35 (m, 1H), 7.66 (s, 1H), 9.03 (br, 1H). MS (ESI) [*M*−H]<sup>−</sup> 222.4.



**5.1.2. Ethyl 3-acetyl-5-chloro-1H-indole-2-carboxylate (9)**

Acetic anhydride (1.1 ml, 8.94 mmol) was added to an ice-cooled suspension of  $\text{AlCl}_3$  (1.19 g, 8.94 mmol) in 1,2-dichloroethane (16 ml) and the reaction was stirred for 5 min under nitrogen. A solution of **7** (1 g, 4.47 mmol) in 1,2-dichloroethane (16 ml) was added dropwise and the reaction mixture was refluxed for 1 h. After cooling to room temperature, the reaction mixture was added ice water, extracted with ethyl acetate, dried over anhydrous  $\text{MgSO}_4$ , and purified by column chromatography on silica (0–25% ethyl acetate in hexanes) to give the product as off-white solid (0.72 g, 60% yield).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.46 (t,  $J$  = 7.1, 3H), 2.74 (s, 3H), 4.49 (q,  $J$  = 7.2, 2H), 7.34 (m, 2H), 8.12 (s, 1H), 9.18 (br, 1H).

**5.1.3. Ethyl 5-chloro-3-ethyl-1H-indole-2-carboxylate (10)**

To a solution of **9** (0.44 g, 1.66 mmol) in trifluoroacetic acid (4 ml) was added triethylsilane (1.1 ml, 6.64 mmol). The reaction mixture was stirred at room temperature for 3 h. It was then poured into water, extracted with ethyl acetate. The organic layer was washed with 1 N NaOH, water, and brine, dried over anhydrous  $\text{MgSO}_4$ , and concentrated in vacuo to give the desired product as yellow solid (0.4 g, 95% yield).  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.17 (t,  $J$  = 7.4, 3H), 1.35 (t,  $J$  = 7.1, 3H), 3.03 (q,  $J$  = 7.3, 2H), 4.35 (q,  $J$  = 7.0, 2H), 7.25 (m, 1H), 7.42 (d,  $J$  = 8.7, 1H), 7.74 (d,  $J$  = 1.7, 1H), 11.68 (br, 1H).

**5.1.4. 5-Chloro-3-ethyl-1H-indole-2-carboxylic acid (11)**

A solution of **10** (0.40 g, 1.58 mmol) and aqueous 1 N NaOH (2.5 ml) in ethanol (30 ml) was refluxed for 3 h. After the reaction has completed, solvent was removed in vacuo. The residue was dissolved in 5 ml of water and pH was adjusted to 3 by 2 N HCl. White precipitate formed during the reaction was filtered to give the desired product as off-white solid (0.38 g, quantitative yield).  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.17 (t,  $J$  = 7.3, 3H), 3.02 (q,  $J$  = 7.3, 2H), 7.23 (dd,  $J$  = 8.8, 1H), 7.39 (d,  $J$  = 8.7, 1H), 7.71 (d,  $J$  = 1.7, 1H), 11.58 (s, 1H), 13.06 (s, 1H). MS (ESI)  $[\text{M}-\text{H}]^-$  222.4.

**5.1.5. 5-Chloro-*N*-[2-(4-nitrophenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (12)**

To a solution of **11** (0.02 g, 0.06 mmol) in DMF (2 ml) was added 4-nitrophenylethylamine (5.5  $\mu\text{L}$ , 0.06 mmol), BOP (0.026 g, 0.06 mmol), and *N,N*-diisopropylethylamine (26  $\mu\text{L}$ , 0.15 mmol). The reaction mixture was stirred at room temperature for 16 h, and then diluted with water, extracted with ethyl acetate three times. The combined organic layers were washed twice with water, and brine, dried over anhydrous  $\text{MgSO}_4$ , concentrated in vacuo, and purified by column chromatography on silica to give the desired compound as white solid (0.018 g, 54% yield).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.19 (t,  $J$  = 7.6, 3H), 2.82 (q,  $J$  = 7.7, 2H), 3.10 (t,  $J$  = 6.8, 2H), 3.80 (q,  $J$  = 6.6, 2H), 5.99 (br, 1H), 7.21 (m, 2H), 7.24 (m, 1H), 7.31 (m, 2H), 7.42 (s, 1H), 7.58 (d,  $J$  = 1.9, 1H), 8.96 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  361.3,  $[\text{M}-\text{H}]^-$  359.4.

**5.1.6. 3-Ethyl-5-chloro-*N*-[2-(3-nitrophenyl)ethyl]-1H-indole-2-carboxamide (13)**

Prepared using the procedure for compound **12** to give the title product as white solid in 30% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ) 1.14–1.23 (m, 3H), 3.10 (m, 2H), 3.68 (m, 2H), 3.81 (d,  $J$  = 6.22 Hz, 2H), 6.62 (br, 1H), 7.20 (m, 1H), 7.31 (s, 1H), 7.49 (s, 1H), 7.57 (d,  $J$  = 1.70 Hz, 2H), 8.15 (m, 2H), 9.10 (br, 1H).

**5.1.7. *N*-[2-(4-Aminophenyl)ethyl]-3-ethyl-5-chloro-1H-indole-2-carboxamide (14)**

To a suspension of **12** (0.71 g, 1.91 mmol) in ethanol (20 ml) was added hydrazine hydrate (1.4 ml, 28.6 mmol) and the reaction mixture was stirred at 50 °C for 15 min until the starting material is dissolved completely. Excess of Raney Nickel (0.5 g) was added

to the reaction mixture and the reaction was maintained at 50 °C. After about 1 h when gas evolution ceased, Raney Nickel was filtered under vacuum. The filtrate was concentrated in vacuo to give the desired product as white solid (0.3 g, 46% yield).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.12 (m, 3H), 2.72 (q,  $J$  = 7.6, 2H), 2.86 (t,  $J$  = 6.6, 2H), 3.76 (q,  $J$  = 6.5, 2H), 5.97 (br, 1H), 6.68 (m, 2H), 7.05 (m, 2H), 7.21 (m, 1H), 7.37 (m, 1H), 7.54 (m, 1H), 8.98 (br, 1H).

**5.1.8. *N*-[2-(3-Aminophenyl)ethyl]-3-ethyl-5-chloro-1H-indole-2-carboxamide (15)**

Prepared using the procedure for compound **14** to give the title product as white solid in 70% yield.  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ) 1.12 (m, 3H), 3.04 (m, 2H), 3.68 (m, 2H), 7.04 (m, 1H), 7.20 (m, 1H), 7.26 (m, 1H), 7.38 (m, 1H), 7.46 (m, 2H), 7.58 (m, 1H).

**5.1.9. 5-Chloro-*N*-[2-[4-(dimethylamino)phenyl]ethyl]-3-ethyl-1H-indole-2-carboxamide (16)**

To a solution of **14** (0.03 g, 0.09 mmol) in methanol (1 mL), 37% formaldehyde (1 mL) was added followed by acetic acid (18  $\mu\text{L}$ ) and  $\text{NaCNBH}_4$  (0.027 g, 0.44 mmol). After stirring at room temperature for 16 h, the reaction was quenched with 1 N HCl and extracted with ethyl acetate three times. The combined organic fractions was washed with saturated  $\text{NaHCO}_3$  and brine, dried over anhydrous  $\text{MgSO}_4$ , concentrated in vacuo, and purified by column chromatography on silica (0–10% MeOH in DCM) to give the desired product as yellow solid (0.015 mg, 47% yield).  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.12 (t,  $J$  = 7.4, 3H), 2.74 (t,  $J$  = 7.3, 2H), 2.84 (s, 6H), 2.95 (q,  $J$  = 7.4, 2H), 3.45 (m, 2H), 6.68 (d,  $J$  = 8.7, 2H), 7.04 (d,  $J$  = 2.4, 1H), 7.08 (d,  $J$  = 9.0, 2H), 7.37 (m, 2H), 7.90 (m, 1H), 11.20 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  370.3,  $[\text{M}-\text{H}]^-$  368.5.

**5.1.10. 5-Chloro-*N*-[2-[4-(diethylamino)phenyl]ethyl]-3-ethyl-1H-indole-2-carboxamide (17)**

To a solution of **14** (0.015 g, 0.044 mmol) and acetaldehyde (6.5  $\mu\text{L}$ , 0.11 mmol) in 1,2-dichloroethane (2 ml) was stirred at room temperature for 30 min before  $\text{Na}(\text{OAc})_3\text{BH}$  (0.023 g, 0.11 mmol) was added. The reaction continued at room temperature for another 16 h before it was quenched with 1 N NaOH. The reaction mixture was extracted with dichloromethane. The organic layer was washed with water and brine, dried over anhydrous  $\text{MgSO}_4$ , concentrated in vacuo, and purified by column chromatography on silica (0–10% MeOH in DCM) to give the desired product as white solid (0.012 g, 69% yield).  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  1.06 (t,  $J$  = 7.0, 6H), 1.12 (t,  $J$  = 7.4, 3H), 2.72 (m, 2H), 2.95 (m, 2H), 3.29 (q,  $J$  = 7.2, 4H), 3.43 (m, 2H), 6.60 (d,  $J$  = 8.5, 2H), 7.04 (d,  $J$  = 8.5, 2H), 7.18 (dd,  $J_1$  = 1.7,  $J_2$  = 8.7, 1H), 7.39 (d,  $J$  = 8.7, 1H), 7.93 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  398.3,  $[\text{M}-\text{H}]^-$  396.5.

**5.1.11. 5-Chloro-*N*-[2-[4-(dipropylamino)phenyl]ethyl]-3-ethyl-1H-indole-2-carboxamide (18)**

Prepared using the procedure for compound **17** to give the desired product as white solid in 65% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.92 (t,  $J$  = 7.3, 6H), 1.06 (t,  $J$  = 7.9, 3H), 1.60 (m, 4H), 2.71 (m, 2H), 2.85 (t,  $J$  = 6.6, 2H), 3.22 (t,  $J$  = 7.5, 4H), 3.76 (q,  $J$  = 6.2, 2H), 5.99 (s, 1H), 6.62 (d,  $J$  = 8.5, 2H), 7.08 (d,  $J$  = 8.5, 2H), 7.21 (m, 1H), 7.29 (m, 1H), 7.54 (s, 1H), 9.11 (s, 1H). MS (ESI)  $[\text{M}]^+$  426.3.

**5.1.12. 5-Chloro-*N*-[2-[4-(hexylamino)phenyl]ethyl]-3-ethyl-1H-indole-2-carboxamide (19)**

Prepared using the procedure for compound **17** to give the desired product as white solid in 32% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.91 (t,  $J$  = 7.5, 3H), 1.10 (t,  $J$  = 7.3, 3H), 1.35 (m, 6H), 1.62 (m, 2H), 2.71 (q,  $J$  = 7.8, 2H), 2.85 (t,  $J$  = 6.5, 2H), 3.10 (t,  $J$  = 7.1, 2H), 3.76 (q,  $J$  = 6.0, 2H), 5.98 (s, 1H), 6.59 (d,  $J$  = 7.7, 2H), 7.06 (d,  $J$  = 8.3, 2H), 7.21 (m, 2H), 7.31 (m, 1H), 7.54 (s, 1H), 8.96 (s, 1H). MS (ESI)  $[\text{M}]^+$  426.3.

**5.1.13. 5-Chloro-N-[2-[3-(dimethylamino)phenyl]ethyl]-3-ethyl-1H-indole-2-carboxamide (20)**

Prepared using the procedure for compound **17** to give the title product as light yellow solid in 54% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.07 (t,  $J = 7.6$ , 3H), 2.70 (d,  $J = 7.5$ , 2H), 2.84 (s, 6H), 2.95 (t,  $J = 6.6$ , 2H), 3.80 (m, 2H), 5.86 (br, 1H), 6.77–6.90 (m, 3H), 7.15–7.38 (m, 4H), 7.54 (d,  $J = 1.9$ , 1H), 9.04 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  370.3.

**5.1.14. N-[2-(4-Acetylphenyl)ethyl]-5-chloro-3-ethyl-1H-indole-2-carboxamide (21)**

To a solution of **14** (0.020 g, 0.058 mmol) in THF (0.3 ml) was added triethylamine (12  $\mu\text{L}$ , 0.088 mmol) and acetyl chloride (6  $\mu\text{L}$ , 0.088 mmol). The reaction mixture was refluxed for 4 h. The solvent was removed under vacuum. The residue was dissolved in dichloromethane. The solution was then washed with 1 N HCl and brine, dried over anhydrous  $\text{MgSO}_4$ , and concentrated in vacuo to give the desired product as white solid in 59% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.13 (t,  $J = 7.7$ , 3H), 2.19 (s, 3H), 2.76 (m, 2H), 2.94 (t,  $J = 6.5$ , 2H), 3.79 (q,  $J = 6.2$ , 2H), 5.97 (s, 1H), 7.13 (m, 1H), 7.22 (d,  $J = 9.0$ , 2H), 7.29 (m, 1H), 7.47 (d,  $J = 8.3$ , 2H), 7.54 (s, 1H), 8.91 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  384.4,  $[\text{M}-\text{H}]^-$  382.4.

**5.1.15. N-[2-(4-Butanoylphenyl)ethyl]-5-chloro-3-ethyl-1H-indole-2-carboxamide (22)**

Prepared using the procedure for compound **12** to give the title product as white solid (0.012 g, 50% yield).  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ )  $\delta$  0.99 (t,  $J = 7.3$ , 3H), 1.19 (t,  $J = 7.7$ , 3H), 1.71 (m, 2H), 2.33 (t,  $J = 7.3$ , 2H), 2.94 (m, 4H), 3.63 (t,  $J = 7.3$ , 2H), 7.17 (d,  $J = 8.7$ , 1H), 7.24 (d,  $J = 8.1$ , 2H), 7.33 (d,  $J = 8.7$ , 1H), 7.49 (d,  $J = 8.3$ , 2H), 7.58 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  412.4,  $[\text{M}+\text{Na}]^+$  434.3,  $[\text{M}-\text{H}]^-$  410.6.

**5.1.16. 5-Chloro-3-ethyl-N-[2-(4-hexanoylphenyl)ethyl]-1H-indole-2-carboxamide (23)**

Prepared using the procedure for compound **12** to give the title product as white solid in 60% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.89 (t,  $J = 7.7$ , 3H), 1.11 (m, 5H), 1.69–1.81 (m, 2H), 2.36 (t,  $J = 7.54$  Hz, 2H), 2.67–2.89 (m, 4H), 2.94 (t,  $J = 6.69$  Hz, 2H), 3.63 (br, 1H), 3.73–3.83 (m, 2H), 5.96 (br, 1H), 6.68 (d,  $J = 8.3$ , 1H), 7.08 (d,  $J = 9.0$ , 2H), 7.23 (m, 1H), 7.49 (d,  $J = 8.3$ , 2H), 7.54 (s, 1H), 8.91 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  440.2,  $[\text{M}+\text{Na}]^+$  462.5,  $[\text{M}-\text{H}]^-$  438.5.

**5.1.17. 5-Chloro-3-ethyl-N-(2-phenylethyl)-1H-indole-2-carboxamide (24)**

Prepared using the procedure for compound **12** to give the title product as white solid in 60% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.99 (t,  $J = 7.6$ , 3H), 2.62 (q,  $J = 7.0$ , 2H), 2.93 (t,  $J = 6.6$ , 2H), 3.76 (t,  $J = 6.2$ , 2H), 5.89 (s, 1H), 7.15 (m, 1H), 7.19–7.30 (m, 6H), 7.47 (s, 1H), 9.10 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  327.3,  $[\text{M}+\text{Na}]^+$  349.4,  $[\text{M}-\text{H}]^-$  325.3.

**5.1.18. 5-Chloro-N-[2-(4-chlorophenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (25)**

Prepared using the procedure for compound **12** to give the title product as white solid in 50% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.14 (t,  $J = 7.68$  Hz, 3H), 2.71–2.82 (m, 2H), 2.97 (t,  $J = 6.78$  Hz, 2H), 3.82 (q,  $J = 6.56$  Hz, 2H), 6.04 (br s, 1H), 7.26–7.39 (m, 6H), 7.58 (d,  $J = 1.41$  Hz, 1H), 9.30 (br s, 1H). MS (ESI)  $[\text{M}-\text{H}]^-$  359.5.

**5.1.19. 5-Chloro-N-[2-(4-methoxyphenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (26)**

Prepared using the procedure for compound **12** to give the title product as white solid in 50% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.09 (t,  $J = 7.7$ , 3H), 2.71 (q,  $J = 7.7$ , 2H), 2.92 (t,  $J = 6.7$ , 2H), 3.80 (m, 5H), 5.98 (s, 1H), 6.89 (d,  $J = 8.8$ , 2H), 7.18 (d,  $J = 8.7$ , 2H), 7.22 (d,  $J = 1.9$ , 1H), 7.31 (d,  $J = 8.7$ , 1H), 7.55 (s, 1H), 9.28 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  357.2,  $[\text{M}-\text{H}]^-$  355.4.

**5.1.20. 5-Chloro-N-[2-(4-tert-butylphenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (27)**

Prepared using the procedure for compound **12** to give the title product as white solid in 87% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.01 (t,  $J = 7.7$ , 3H), 2.66 (q,  $J = 7.7$ , 2H), 2.94 (m, 2H), 3.84 (q,  $J = 6.3$ , 2H), 5.99 (s, 1H), 7.19 (m, 3H), 7.34 (m, 3H), 7.53 (d,  $J = 1.9$ , 1H), 9.73 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  383.3,  $[\text{M}-\text{H}]^-$  381.5.

**5.1.21. 5-Chloro-N-[2-(2-chlorophenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (28)**

Prepared using the procedure for compound **12** to give the title product as white solid in 34% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.15 (t,  $J = 7.7$ , 3H), 2.79 (q,  $J = 7.7$ , 2H), 3.14 (t,  $J = 6.8$ , 2H), 3.85 (q,  $J = 6.6$ , 2H), 6.01 (br, 1H), 7.20–7.23 (m, 3H), 7.28–7.33 (m, 2H), 7.56 (d,  $J = 1.9$ , 1H), 9.23 (br, 1H). MS (ESI)  $[\text{M}+\text{Na}]^+$  382.5,  $[\text{M}-\text{H}]^-$  359.3.

**5.1.22. 5-Chloro-N-[2-(3-chlorophenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (29)**

Prepared using the procedure for compound **12** to give the title product as white solid in 37% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.12 (t,  $J = 7.7$ , 3H), 2.74 (q,  $J = 7.6$ , 2H), 2.96 (t,  $J = 6.8$ , 2H), 3.81 (q,  $J = 6.4$ , 2H), 5.96 (br, 1H), 7.15 (m, 1H), 7.22 (m, 2H), 7.31 (m, 3H), 7.56 (d,  $J = 2.1$ , 1H), 9.07 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  361.3,  $[\text{M}-\text{H}]^-$  359.5.

**5.1.23. 5-Chloro-N-[2-(3-methoxyphenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (30)**

Prepared using the procedure for compound **12** to give the title product as white solid in 25% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.07 (t,  $J = 7.6$ , 3H), 2.70 (d,  $J = 7.5$ , 2H), 2.95 (t,  $J = 6.6$ , 2H), 3.72–3.96 (m, 5H), 5.86 (br, 1H), 6.77–6.90 (m, 3H), 7.15–7.38 (m, 4H), 7.54 (d,  $J = 1.9$ , 1H), 9.04 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  357.2.

**5.1.24. 5-Chloro-N-[2-(3-hydroxyphenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (31)**

Prepared using the procedure for compound **12** to give the title product as white solid in 29% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.07 (t,  $J = 7.6$ , 3H), 2.69 (q,  $J = 7.6$ , 2H), 2.89 (t,  $J = 6.6$ , 2H), 3.79 (m, 2H), 6.06 (s, 1H), 6.79 (m, 3H), 7.18 (m, 3H), 7.51 (s, 1H), 9.28 (s, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  343.5,  $[\text{M}-\text{H}]^-$  341.5.

**5.1.25. 5-Chloro-N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (32)**

Prepared using the procedure for compound **12** to give the title product as white solid in 36% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.09 (t,  $J = 7.6$ , 3H), 2.73 (m, 2H), 2.90 (t,  $J = 6.7$ , 2H), 3.79 (m, 2H), 3.85 (s, 3H), 6.76 (m, 2H), 6.89 (d,  $J = 8.5$ , 1H), 7.21 (m, 1H), 7.31 (m, 1H), 7.55 (s, 1H), 9.28 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  373.2,  $[\text{M}-\text{H}]^-$  371.4.

**5.1.26. 5-Chloro-N-[2-(3,4-dichlorophenyl)ethyl]-3-ethyl-1H-indole-2-carboxamide (33)**

Prepared using the procedure for compound **12** to give the title product as white solid in 23% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.16 (t,  $J = 7.82$  Hz, 3H), 2.79 (q,  $J = 7.79$  Hz, 2H), 3.10 (m, 2H), 3.85 (q,  $J = 6.53$  Hz, 2H), 6.01 (br s, 1H), 7.29–7.35 (m, 1H), 7.44 (d,  $J = 8.67$  Hz, 2H), 7.57 (s, 1H), 8.21 (d,  $J = 8.29$  Hz, 2H), 9.01 (br s, 1H). MS (ESI)  $[\text{M}]^+$  394.1.

**5.1.27. N-[2-(2H-1,3-Benzodioxol-5-yl)ethyl]-5-chloro-3-ethyl-1H-indole-2-carboxamide (34)**

Prepared using the procedure for compound **12** to give the title product as white solid in 33% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.13 (t,  $J = 7.6$ , 3H), 2.74 (q,  $J = 7.6$ , 2H), 2.89 (t,  $J = 7.0$ , 2H), 3.77 (q,  $J = 6.2$ , 2H), 5.96 (s, 2H), 6.71 (m, 1H), 6.77 (m, 2H), 7.21 (m, 1H),



7.30 (m, 1H), 7.55 (d,  $J = 1.9$ , 1H), 8.99 (br, 1H). MS (ESI)  $[M+H]^+$  371.4,  $[M-H]^-$  369.5.

**5.1.28. 5-Chloro-*N*-{3-[6-(dimethylamino)pyridin-2-yl]phenyl}-3-ethyl-1*H*-indole-2-carboxamide (35)**

Prepared using the procedure for compound **12** to give the title product as white solid in 40% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.46 (t,  $J = 7.63$  Hz, 3H), 3.12 (q,  $J = 7.72$  Hz, 2H), 3.18 (s, 6H), 6.52 (d,  $J = 8.29$  Hz, 1H), 7.07 (d,  $J = 7.16$  Hz, 1H), 7.24 (d,  $J = 2.07$  Hz, 1H), 7.32–7.38 (m, 1H), 7.47 (t,  $J = 8.01$  Hz, 1H), 7.54 (dd,  $J = 7.54$ , 8.48 Hz, 1H), 7.65 (d,  $J = 2.07$  Hz, 1H), 7.78 (dd,  $J = 1.22$ , 8.01 Hz, 1H), 7.84 (d,  $J = 6.22$  Hz, 2H), 8.20 (t,  $J = 1.79$  Hz, 1H), 9.09 (br s, 2H). MS (ESI)  $[M+H]^+$  419.7,  $[M-H]^-$  417.4.

**5.1.29. 5-Chloro-3-ethyl-2-(4-phenylpiperazine-1-carbonyl)-1*H*-indole (36)**

Prepared using the procedure for compound **12** to give the title product as white solid in 45% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.31 (t,  $J = 7.6$ , 3H), 2.81 (q,  $J = 7.5$ , 2H), 3.22 (m, 2H), 3.86 (m, 2H), 6.94 (d,  $J = 7.9$ , 2H), 7.22–7.32 (m, 5H), 7.63 (d,  $J = 1.7$ , 1H), 8.46 (br, 1H). MS (ESI)  $[M+H]^+$  368.1,  $[M-H]^-$  366.6.

**5.1.30. 5-Chloro-2-[4-(4-chlorophenyl)piperazine-1-carbonyl]-3-ethyl-1*H*-indole (37)**

Prepared using the procedure for compound **12** to give the title product as white solid in 80% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.30 (t,  $J = 7.6$ , 3H), 2.79 (q,  $J = 7.6$ , 2H), 3.18 (m, 4H), 3.84 (m, 4H), 6.84 (d,  $J = 9.0$ , 2H), 7.18–7.29 (m, 4H), 7.61 (s, 1H), 8.78 (s, 1H). MS (ESI)  $[M]^+$  402.3.

**5.1.31. *tert*-Butyl *N*-[2-(4-aminophenyl)ethyl]carbamate (39)**

To a solution of 2-(4-nitrophenyl)ethan-1-amine (**38**, 0.3 g, 1.48 mmol) in 1,4-dioxane (4 ml) and water (1.5 ml), 1 N NaOH was added and the reaction mixture was cooled to 0 °C. Upon addition of  $\text{Boc}_2\text{O}$ , the reaction was stirred at room temperature for 1 h. After no starting material was detected on TLC, solvent was removed in vacuo and the solid residue was dissolved in dichloromethane, washed with water and brine, dried over anhydrous  $\text{MgSO}_4$ , and concentrated in vacuo to give the desired product as white solid (0.386 g, 98% yield).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.43 (s, 9H), 2.92 (t,  $J = 6.6$ , 2H), 3.41 (t,  $J = 6.6$ , 2H), 4.56 (br, 1H), 7.36 (d,  $J = 8.5$ , 2H), 8.17 (d,  $J = 8.7$ , 2H). This intermediate underwent the reduction procedure for **14** to give the title product as white solid in 85% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.43 (s, 9H), 2.68 (t,  $J = 6.9$ , 2H), 3.32 (t,  $J = 6.2$ , 2H), 3.59 (br, 2H), 6.64 (d,  $J = 8.3$ , 2H), 6.98 (d,  $J = 8.1$ , 2H).

**5.1.32. *tert*-Butyl *N*-[2-[4-(diethylamino)phenyl]ethyl] maximum carbamate (40)**

Prepared using the procedure for compound **17** to give the title product as colorless oil in 85% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.14 (t,  $J = 7.1$ , 6H), 1.43 (s, 9H), 2.67 (t,  $J = 6.9$ , 2H), 3.33 (m, 6H), 4.56 (br, 1H), 6.63 (d,  $J = 8.7$ , 2H), 7.03 (d,  $J = 8.7$ , 2H).

**5.1.33. *tert*-Butyl *N*-[2-[4-(piperidin-1-yl)phenyl]ethyl] carbamate (41)**

A microwave vial containing **39** (0.05 g, 0.21 mmol), 1,5-dibromopentane (31  $\mu\text{L}$ , 0.23 mmol), potassium carbonate (0.032 g, 0.23 mmol) in water (2 ml) was irradiated at 120 °C for 20 min (maximum pressure: 17 psi, power: 200 W, PowerMax: off, ramp: 2 min). The reaction mixture was extracted with ethyl acetate, dried over anhydrous  $\text{MgSO}_4$ , and concentrated in vacuo to give the desired product as yellow solid (0.03 g, 47% yield).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.43 (s, 9H), 1.57 (m, 2H), 2.17 (m, 4H), 2.70 (t,  $J = 6.9$ , 2H), 3.12 (m, 4H), 3.32 (m, 2H), 6.88 (d,  $J = 8.7$ , 2H), 7.07 (d,  $J = 8.5$ , 2H).

**5.1.34. 5-Fluoro-*N*-{2-[4-(diethylamino)phenyl]ethyl}-3-ethyl-1*H*-indole-2-carboxamide (42)**

Prepared using the procedure for compound **12** to give the title product as white solid in 54% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.08 (t,  $J = 7.6$ , 3H), 1.15 (t,  $J = 7.1$ , 6H), 2.69 (m, 2H), 2.86 (t,  $J = 6.6$ , 2H), 3.34 (q,  $J = 7.0$ , 4H), 3.78 (q,  $J = 6.5$ , 2H), 6.04 (s, 1H), 6.66 (d,  $J = 8.7$ , 2H), 7.02 (m, 1H), 7.10 (d,  $J = 8.7$ , 2H), 7.20 (dd,  $J_1 = 9.6$ ,  $J_2 = 2.4$ , 1H), 7.31 (dd,  $J_1 = 8.9$ ,  $J_2 = 4.3$ , 1H), 9.40 (br, 1H). MS (ESI)  $[M+H]^+$  382.5,  $[M-H]^-$  380.6.

**5.1.35. 5-Fluoro-*N*-{2-[4-(diethylamino)phenyl]ethyl}-3-methyl-1*H*-indole-2-carboxamide (43)**

Prepared using the procedure for compound **12** to give the title product as white solid in 53% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.15 (t,  $J = 7.0$ , 6H), 2.29 (s, 3H), 2.86 (t,  $J = 6.7$ , 2H), 3.34 (q,  $J = 7.2$ , 4H), 3.76 (q,  $J = 6.4$ , 2H), 6.06 (s, 1H), 6.66 (d,  $J = 8.7$ , 2H), 7.01 (m, 1H), 7.09 (d,  $J = 8.7$ , 2H), 7.19 (dd,  $J_1 = 9.5$ ,  $J_2 = 2.4$ , 1H), 7.31 (m, 1H), 9.54 (br, 1H). MS (ESI)  $[M+H]^+$  368.4,  $[M-H]^-$  366.6.

**5.1.36. 5-Fluoro-*N*-{2-[4-(diethylamino)phenyl]ethyl}-1*H*-indole-2-carboxamide (44)**

Prepared using the procedure for compound **12** to give the title product as white solid in 33% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.17 (t,  $J = 7.1$ , 6H), 2.83 (t,  $J = 6.8$ , 2H), 3.35 (q,  $J = 7.2$ , 4H), 3.69 (q,  $J = 6.6$ , 2H), 6.19 (s, 1H), 6.67 (m, 3H), 7.02 (m, 1H), 7.08 (m, 2H), 7.25 (m, 1H), 7.37 (dd,  $J_1 = 8.9$ ,  $J_2 = 4.4$ , 1H), 9.38 (br, 1H). MS (ESI)  $[M+H]^+$  354.5,  $[M-H]^-$  352.4.

**5.1.37. 5-Chloro-*N*-{2-[4-(diethylamino)phenyl]ethyl}-1*H*-indole-2-carboxamide (45)**

Prepared using the procedure for compound **12** to give the title product as white solid in 30% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.17 (t,  $J = 7.1$ , 6H), 2.84 (t,  $J = 6.8$ , 2H), 3.35 (q,  $J = 7.0$ , 4H), 3.69 (m, 2H), 6.25 (s, 1H), 6.65 (m, 3H), 7.09 (d,  $J = 8.7$ , 2H), 7.22 (m, 1H), 7.38 (m, 1H), 7.58 (s, 1H), 9.78 (br, 1H). MS (ESI)  $[M+H]^+$  370.3,  $[M-H]^-$  368.5.

**5.1.38. 5-Fluoro-3-ethyl-*N*-[2-[4-(piperidin-1-yl)phenyl]ethyl]-1*H*-indole-2-carboxamide (46)**

Prepared using the procedure for compound **12** to give the title product as white solid in 95% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.08 (t,  $J = 7.7$ , 3H), 1.58 (m, 2H), 1.71 (m, 4H), 2.70 (q,  $J = 7.7$ , 2H), 2.89 (t,  $J = 6.6$ , 2H), 3.12 (m, 4H), 3.79 (q,  $J = 6.4$ , 2H), 6.02 (s, 1H), 6.91 (d,  $J = 8.7$ , 2H), 7.01 (m, 1H), 7.14 (d,  $J = 8.7$ , 2H), 7.20 (dd,  $J_1 = 9.4$ ,  $J_2 = 2.4$ , 1H), 7.31 (m, 1H), 9.46 (br, 1H). MS (ESI)  $[M+H]^+$  394.6,  $[M-H]^-$  392.7.

**5.1.39. 5-Fluoro-3-methyl-*N*-[2-[4-(piperidin-1-yl)phenyl]ethyl]-1*H*-indole-2-carboxamide (47)**

Prepared using the procedure for compound **12** to give the title product as white solid in 96% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.59 (m, 2H), 1.72 (m, 4H), 2.28 (s, 3H), 2.88 (t,  $J = 6.6$ , 2H), 3.13 (m, 4H), 3.77 (q,  $J = 6.3$ , 2H), 6.02 (s, 1H), 6.92 (d,  $J = 8.5$ , 2H), 7.03 (m, 1H), 7.13 (d,  $J = 8.5$ , 2H), 7.19 (dd,  $J_1 = 9.5$ ,  $J_2 = 2.2$ , 1H), 7.31 (m, 1H), 9.41 (br, 1H). MS (ESI)  $[M+H]^+$  380.3,  $[M-H]^-$  378.5.

**5.1.40. 5-Fluoro-*N*-{2-[4-(piperidin-1-yl)phenyl]ethyl}-1*H*-indole-2-carboxamide (48)**

Prepared using the procedure for compound **12** to give the title product as white solid in 55% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.26 (m, 2H), 1.72 (m, 4H), 2.85 (t,  $J = 6.8$ , 2H), 3.13 (m, 4H), 3.70 (q,  $J = 6.6$ , 2H), 6.14 (s, 1H), 6.63 (d,  $J = 1.3$ , 1H), 6.93 (d,  $J = 8.7$ , 2H), 7.04 (m, 1H), 7.12 (d,  $J = 8.7$ , 2H), 7.24 (m, 1H), 7.36 (m, 1H), 9.21 (br, 1H). MS (ESI)  $[M+H]^+$  366.5,  $[M-H]^-$  364.6.

### 5.1.41. 5-Chloro-N-[2-[4-(piperidin-1-yl)phenyl]ethyl]-1H-indole-2-carboxamide (49)

Prepared using the procedure for compound **14** to give the title product as white solid in 30% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.26 (m, 2H), 1.72 (m, 4H), 2.85 (t,  $J = 6.8$ , 2H), 3.15 (m, 4H), 3.70 (q,  $J = 6.6$ , 2H), 6.15 (s, 1H), 6.61 (d,  $J = 1.5$ , 1H), 6.92 (d,  $J = 8.7$ , 2H), 7.12 (d,  $J = 8.7$ , 2H), 7.23 (m, 1H), 7.36 (d,  $J = 8.7$ , 1H), 7.59 (d,  $J = 1.9$ , 1H), 9.32 (br, 1H). MS (ESI)  $[\text{M}+\text{H}]^+$  382.5,  $[\text{M}-\text{H}]^-$  380.5.

## 5.2. Biological assays

### 5.2.1. CB1 calcium mobilization assay

CHO-RD-HGA16 cells (Molecular Devices, USA) stably expressing the human CB1 receptor were used. The day before the assay, cells were plated into 96-well black-walled assay plates at 25,000 cells/well in Ham's F12 supplemented with 10% fetal bovine serum, 100 units of penicillin, 100 units of streptomycin, and 100  $\mu\text{g}/\text{mL}$  Normocin<sup>TM</sup>. The cells were incubated overnight at 37 °C, 5%  $\text{CO}_2$ . Prior to the assay, Calcium 5 dye (Molecular Devices, USA) was reconstituted according to the manufacturer's instructions. The reconstituted dye was diluted 1:40 in pre-warmed (37 °C) assay buffer (1 $\times$  HBSS, 20 mM HEPES, 2.5 mM probenecid, pH 7.4 at 37 °C). Growth medium was removed and the cells were gently washed with 100  $\mu\text{L}$  of pre-warmed (37 °C) assay buffer. The cells were incubated for 45 min at 37 °C, 5%  $\text{CO}_2$  in 200  $\mu\text{L}$  of the diluted Calcium 5 dye. For antagonist ( $\text{IC}_{50}$ ) assays, the  $\text{EC}_{80}$  concentration of CP55,940 was prepared at 10 $\times$  the desired final concentration in 0.25% BSA/0.5% DMSO/0.5% EtOH/assay buffer, aliquoted into 96-well polypropylene plates, and warmed to 37 °C. Serial dilutions of the test compounds were prepared at 10 $\times$  the desired final concentration in 2.25% BSA/4.5% DMSO/4.5% EtOH/assay buffer. After the dye-loading incubation period, the cells were pre-treated with 25  $\mu\text{L}$  of the test compound serial dilutions and incubated for 15 min at 37 °C. After the pre-treatment incubation period, the plate was read with a FLIPR Tetra (Molecular Devices, USA). Calcium-mediated changes in fluorescence were monitored every 1 s over a 90 s time period, with the Tetra adding 25  $\mu\text{L}$  of the CP55,940  $\text{EC}_{80}$  concentration at the 10 s time point (excitation at 470–495 nm, detection at 515–575 nm). FLIPR traces were normalized by trace alignment at the last time point before agonist addition (ScreenWorks software, Molecular Devices, USA). Relative fluorescence units (RFU) were plotted against log compound concentration. Data were fit to a three-parameter logistic curve to generate  $\text{IC}_{50}$  values (GraphPad Prism 6.0, GraphPad Software, Inc., San Diego, CA). For the modulation experiments, the above procedure was followed except that cells were pre-treated with a single concentration of test compound (prepared at 10 $\times$  the desired concentration in 2.25% BSA/4.5% DMSO/4.5% EtOH/assay buffer) and the Tetra added serial dilutions of CP55,940 (prepared at 10 $\times$  the desired concentration in 0.25% BSA/0.5% DMSO/0.5% EtOH/assay buffer). For agonist screens, the above procedure was followed except that cells were pre-treated with 2.25% BSA/4.5% DMSO/4.5% EtOH/assay buffer and the Tetra added single concentration dilutions of the test compounds prepared at 10 $\times$  the desired final concentration in 0.25% BSA/0.5% DMSO/0.5% EtOH/assay buffer. Test compound RFUs were compared to the CP55,940  $E_{\text{max}}$  RFUs to generate %  $E_{\text{max}}$  values.

### 5.2.2. CB2 calcium mobilization assay

The CB2 assay used CHO-RD-HGA16 cells (Molecular Devices, USA) stably expressing the human CB2 receptor. This assay was carried out in a similar manner as the CB1 assay except that cells were plated at a density of 30,000 cells/well.

## Acknowledgments

We thank Tiffany Langston for technical assistance and David Perrey for the critical reading of the manuscript. This work was supported by National Institute on Drug Abuse, National Institutes of Health, USA (grants DA032837 and DA003672), and by the National Natural Science Foundation of China (81473089).

## Supplementary data

Supplementary data (agonist screens at the CB1 and CB2 receptors and HPLC analysis of target compounds) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2015.02.058>. These data include MOL files and InChIKeys of the most important compounds described in this article.

## References and notes

- Battista, N.; Di Tommaso, M.; Bari, M.; Maccarrone, M. *Front. Behav. Neurosci.* **2012**, *6*, 9.
- Di Marzo, V. *Pharmacol. Res.* **2009**, *60*, 77.
- Di, M.; Bisogno, T.; De Petrocellis, L. *Curr. Pharm. Des.* **2000**, *6*, 1361.
- Mackie, K. *Annu. Rev. Pharmacol. Toxicol.* **2006**, *46*, 101.
- Howlett, A. C.; Breivogel, C. S.; Childers, S. R.; Deadwyler, S. A.; Hampson, R. E.; Porriño, L. J. *Neuropharmacology* **2004**, *47*, 345.
- Pertwee, R. G. *AAPS J.* **2005**, *7*, E625.
- Makriyannis, A. *J. Med. Chem.* **2014**, *57*, 3891.
- Pertwee, R. G. *Int. J. Obes. (Lond.)* **2006**, *30*, S13.
- Jagerovic, N.; Fernandez-Fernandez, C.; Goya, P. *Curr. Top. Med. Chem.* **2008**, *8*, 205.
- Ross, R. A. *Br. J. Pharmacol.* **2007**, *152*, 565.
- Ross, R. A. *Trends Pharmacol. Sci.* **2007**, *28*, 567.
- Shore, D. M.; Baillie, G. L.; Hurst, D. H.; Navas, F., 3rd; Seltzman, H. H.; Marcu, J. P.; Abood, M. E.; Ross, R. A.; Reggio, P. H. *J. Biol. Chem.* **2014**, *289*, 5828.
- Ahn, K. H.; Mahmoud, M. M.; Kendall, D. A. *J. Biol. Chem.* **2012**, *287*, 12070.
- Horswill, J. G.; Bali, U.; Shaaban, S.; Keily, J. F.; Jeevaratnam, P.; Babbs, A. J.; Reynet, C.; Wong Kai In, P. *Br. J. Pharmacol.* **2007**, *152*, 805.
- Navarro, H. A.; Howard, J. L.; Pollard, G. T.; Carroll, F. I. *Br. J. Pharmacol.* **2009**, *156*, 1178.
- Pamplona, F. A.; Ferreira, J.; Menezes de Lima, O., Jr.; Duarte, F. S.; Bento, A. F.; Forner, S.; Villarinho, J. G.; Bellocchio, L.; Wotjak, C. T.; Lerner, R.; Monory, K.; Lutz, B.; Canetti, C.; Matias, I.; Calixto, J. B.; Marsicano, G.; Guimaraes, M. Z.; Takahashi, R. N. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *109*, 21134.
- Kenakin, T.; Miller, L. J. *Pharmacol. Rev.* **2010**, *62*, 265.
- Conn, P. J.; Christopoulos, A.; Lindsley, C. W. *Nat. Rev. Drug Disc.* **2009**, *8*, 41.
- Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopoulos, A.; Conn, P. J.; Lindsley, C. W. *J. Med. Chem.* **2012**, *55*, 1445.
- Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R. G.; Ross, R. A. *Mol. Pharmacol.* **2005**, *68*, 1484.
- Baillie, G. L.; Horswill, J. G.; Anavi-Goffer, S.; Reggio, P. H.; Bolognini, D.; Abood, M. E.; McAllister, S.; Strange, P. G.; Stephens, G. J.; Pertwee, R. G.; Ross, R. A. *Mol. Pharmacol.* **2013**, *83*, 322.
- Gamage, T. F.; Ignatowska-Jankowska, B. M.; Wiley, J. L.; Abdelrahman, M.; Trembleau, L.; Greig, I. R.; Thakur, G. A.; Tichkule, R.; Poklis, J.; Ross, R. A.; Pertwee, R. G.; Lichtman, A. H. *Behav. Pharmacol.* **2014**, *25*, 182.
- Ding, Y.; Qiu, Y.; Jing, L.; Thorn, D. A.; Zhang, Y.; Li, J. X. *Pharmacol. Res. Perspect.* **2014**, *2*, e00069.
- Jing, L.; Qiu, Y.; Zhang, Y.; Li, J. X. *Drug Alcohol Depend.* **2014**, *143*, 251.
- Piscitelli, F.; Ligresti, A.; La Regina, G.; Coluccia, A.; Morera, L.; Allara, M.; Novellino, E.; Di Marzo, V.; Silvestri, R. *J. Med. Chem.* **2012**, *55*, 5627.
- Mahmoud, M. M.; Ali, H. I.; Ahn, K. H.; Damaraju, A.; Samala, S.; Pulipati, V. K.; Kolluru, S.; Kendall, D. A.; Lu, D. J. *Med. Chem.* **2013**.
- Khurana, L.; Ali, H. I.; Olszewska, T.; Ahn, K. H.; Damaraju, A.; Kendall, D. A.; Lu, D. J. *Med. Chem.* **2014**, *57*, 3040.
- Ahn, K. H.; Mahmoud, M. M.; Samala, S.; Lu, D.; Kendall, D. A. *J. Neurochem.* **2013**, *124*, 584.
- Murakami, Y.; Watanabe, T.; Takahashi, H.; Yokoo, H.; Nakazawa, Y.; Koshimizu, H.; Adachi, N.; Kurita, M.; Yoshino, T.; Inagaki, T.; Ohishi, M.; Watanabe, M.; Tani, M.; Yokoyama, Y. *Tetrahedron* **1998**, *54*, 45.
- Ju, Y.; Varma, R. S. *J. Org. Chem.* **2006**, *71*, 135.
- Zhang, Y.; Gilliam, A.; Maitra, R.; Damaji, M. I.; Tajuba, J. M.; Seltzman, H. H.; Thomas, B. F. *J. Med. Chem.* **2010**, *53*, 7048.
- Fulp, A.; Bortoff, K.; Zhang, Y.; Seltzman, H.; Mathews, J.; Snyder, R.; Fennell, T.; Maitra, R. *J. Med. Chem.* **2012**, *55*, 10022.
- German, N.; Decker, A. M.; Gilmour, B. P.; Gay, E. A.; Wiley, J. L.; Thomas, B. F.; Zhang, Y. *J. Med. Chem.* **2014**, *57*, 7758.